前列腺癌雄激素受体（AR）靶向治疗现状与探索进展

参考文献：

[1] SOBHANI N, NEELI P K, D’ANGELO A, 等. AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption[J/OL]. International Journal of Molecular Sciences, 2021, 22(11): 5515. DOI:10.3390/ijms22115515.

[2] KU S Y, GLEAVE M E, BELTRAN H. Towards precision oncology in advanced prostate cancer[J/OL]. Nature Reviews. Urology, 2019, 16(11): 645-654. DOI:10.1038/s41585-019-0237-8.

[3] 王硕，杜鹏，杨勇. AR-V7表达与去势抵抗性前列腺癌阿比特龙治疗敏感性的相关性研究[J/OL]. 中华泌尿外科杂志, 2020, 41(3): 200-204. DOI:10.3760/cma.j.cn112330-20200109-00017.

[4] SCHER H I, LU D, SCHREIBER N A, 等. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer[J/OL]. JAMA oncology, 2016, 2(11): 1441-1449. DOI:10.1001/jamaoncol.2016.1828.

[5] BÉKÉS M, LANGLEY D R, CREWS C M. PROTAC targeted protein degraders: the past is prologue[J/OL]. Nature Reviews. Drug Discovery, 2022, 21(3): 181-200. DOI:10.1038/s41573-021-00371-6.

[6] 2024 ASCO Abs 5011